In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and explores the evolving landscape of prostate and bladder cancer treatments. The hosts also share their predictions and insights on how these developments may impact clinical practice.